JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer
Business Wire•13/11/2026•11:30 ET
0
Key Highlights
- ➤PANOVA-3 improved median overall survival statistically significantly with TTFields plus GnP
- ➤Quality-of-life and pain outcomes improved statistically significantly and clinically meaningfully
- ➤TTFields was well-tolerated; no new safety signals emerged in PANOVA-3
- ➤Mild-to-moderate skin adverse events were the most common device-related events
Expert Statements
Teresa Macarulla, MD, PhD, Head of Medical Oncology Department at Hospital Clínic Barcelona Comprehensive Cancer Centre
“The results from the PANOVA-3 trial found that in addition to improving overall survival, Tumor Treating Fields therapy provided clinically meaningful benefits on measures of pain outcomes and quality of life, which are important for clinical decision-making.”
Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure
“The results from the PANOVA-3 trial demonstrated the efficacy of Tumor Treating Fields therapy in locally advanced pancreatic cancer. We also evaluated and saw a positive and clinically meaningful effect from treatment with Tumor Treating Fields on pain, which can significantly affect patients' quality of life. We believe these results can help inform clinicians and patients as they make treatment decisions.”
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer
Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel in patients with unresectable, locally advanced pancreatic adenocarcinoma.
Get started
Create a free account to read the full story.